TWIST1 and breast cancer: Future experiments of xenograft mouse models using syngeneic mouse breast tumor cells with engineered TWIST1 or BRD8 expression in immune-competent mice treated with or without the anti-PD-L1 antibody should help to address whether TWIST1-induced PD-L1 expression truly drives the immune evasion of breast cancer.